vs
Astrana Health, Inc.（ASTH）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Astrana Health, Inc.的季度营收约是Revvity的1.2倍（$950.5M vs $772.1M），Revvity净利率更高（12.7% vs 0.7%，领先12.1%），Astrana Health, Inc.同比增速更快（42.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 9.0%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ASTH vs RVTY — 直观对比
营收规模更大
ASTH
是对方的1.2倍
$772.1M
营收增速更快
ASTH
高出37.0%
5.9%
净利率更高
RVTY
高出12.1%
0.7%
自由现金流更多
RVTY
多$167.7M
$-6.0M
两年增速更快
ASTH
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $772.1M |
| 净利润 | $6.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 1.9% | 14.5% |
| 净利率 | 0.7% | 12.7% |
| 营收同比 | 42.9% | 5.9% |
| 净利润同比 | 184.4% | 3.9% |
| 每股收益（稀释后） | $0.12 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHRVTY
| Q4 25 | $950.5M | $772.1M | ||
| Q3 25 | $956.0M | $698.9M | ||
| Q2 25 | $654.8M | $720.3M | ||
| Q1 25 | $620.4M | $664.8M | ||
| Q4 24 | $665.2M | $729.4M | ||
| Q3 24 | $478.7M | $684.0M | ||
| Q2 24 | $486.3M | $691.7M | ||
| Q1 24 | $404.4M | $649.9M |
净利润ASTHRVTY
| Q4 25 | $6.6M | $98.4M | ||
| Q3 25 | $373.0K | $46.7M | ||
| Q2 25 | $9.4M | $53.9M | ||
| Q1 25 | $6.7M | $42.2M | ||
| Q4 24 | $-7.8M | $94.6M | ||
| Q3 24 | $16.1M | $94.4M | ||
| Q2 24 | $19.2M | $55.4M | ||
| Q1 24 | $14.8M | $26.0M |
毛利率ASTHRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率ASTHRVTY
| Q4 25 | 1.9% | 14.5% | ||
| Q3 25 | 2.0% | 11.7% | ||
| Q2 25 | 3.1% | 12.6% | ||
| Q1 25 | 3.3% | 10.9% | ||
| Q4 24 | 0.1% | 16.3% | ||
| Q3 24 | 5.9% | 14.3% | ||
| Q2 24 | 6.2% | 12.4% | ||
| Q1 24 | 7.5% | 6.8% |
净利率ASTHRVTY
| Q4 25 | 0.7% | 12.7% | ||
| Q3 25 | 0.0% | 6.7% | ||
| Q2 25 | 1.4% | 7.5% | ||
| Q1 25 | 1.1% | 6.4% | ||
| Q4 24 | -1.2% | 13.0% | ||
| Q3 24 | 3.4% | 13.8% | ||
| Q2 24 | 3.9% | 8.0% | ||
| Q1 24 | 3.7% | 4.0% |
每股收益（稀释后）ASTHRVTY
| Q4 25 | $0.12 | $0.86 | ||
| Q3 25 | $0.01 | $0.40 | ||
| Q2 25 | $0.19 | $0.46 | ||
| Q1 25 | $0.14 | $0.35 | ||
| Q4 24 | $-0.14 | $0.77 | ||
| Q3 24 | $0.33 | $0.77 | ||
| Q2 24 | $0.40 | $0.45 | ||
| Q1 24 | $0.31 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $779.3M | $7.3B |
| 总资产 | $2.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASTHRVTY
| Q4 25 | $429.5M | $919.9M | ||
| Q3 25 | $463.4M | $931.4M | ||
| Q2 25 | $342.1M | $991.8M | ||
| Q1 25 | $260.9M | $1.1B | ||
| Q4 24 | $290.8M | $1.2B | ||
| Q3 24 | $350.3M | $1.2B | ||
| Q2 24 | $327.7M | $2.0B | ||
| Q1 24 | $337.3M | $1.7B |
股东权益ASTHRVTY
| Q4 25 | $779.3M | $7.3B | ||
| Q3 25 | $775.5M | $7.4B | ||
| Q2 25 | $765.5M | $7.6B | ||
| Q1 25 | $745.4M | $7.6B | ||
| Q4 24 | $712.7M | $7.7B | ||
| Q3 24 | $704.6M | $7.9B | ||
| Q2 24 | $678.9M | $7.9B | ||
| Q1 24 | $653.5M | $7.8B |
总资产ASTHRVTY
| Q4 25 | $2.2B | $12.2B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $1.4B | $12.4B | ||
| Q1 25 | $1.3B | $12.4B | ||
| Q4 24 | $1.4B | $12.4B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | $1.3B | $13.4B | ||
| Q1 24 | $1.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -0.6% | 21.0% |
| 资本支出强度资本支出/营收 | 0.3% | 2.6% |
| 现金转化率经营现金流/净利润 | -0.44× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $104.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ASTHRVTY
| Q4 25 | $-2.9M | $182.0M | ||
| Q3 25 | $10.0M | $138.5M | ||
| Q2 25 | $90.9M | $134.3M | ||
| Q1 25 | $16.6M | $128.2M | ||
| Q4 24 | $-10.9M | $174.2M | ||
| Q3 24 | $34.0M | $147.9M | ||
| Q2 24 | $23.2M | $158.6M | ||
| Q1 24 | $6.0M | $147.6M |
自由现金流ASTHRVTY
| Q4 25 | $-6.0M | $161.8M | ||
| Q3 25 | $7.4M | $120.0M | ||
| Q2 25 | $89.5M | $115.5M | ||
| Q1 25 | $13.6M | $112.2M | ||
| Q4 24 | $-13.5M | $149.8M | ||
| Q3 24 | $31.7M | $125.6M | ||
| Q2 24 | $20.4M | $136.6M | ||
| Q1 24 | $5.6M | $129.7M |
自由现金流率ASTHRVTY
| Q4 25 | -0.6% | 21.0% | ||
| Q3 25 | 0.8% | 17.2% | ||
| Q2 25 | 13.7% | 16.0% | ||
| Q1 25 | 2.2% | 16.9% | ||
| Q4 24 | -2.0% | 20.5% | ||
| Q3 24 | 6.6% | 18.4% | ||
| Q2 24 | 4.2% | 19.7% | ||
| Q1 24 | 1.4% | 20.0% |
资本支出强度ASTHRVTY
| Q4 25 | 0.3% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.4% | 3.4% | ||
| Q3 24 | 0.5% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% | ||
| Q1 24 | 0.1% | 2.7% |
现金转化率ASTHRVTY
| Q4 25 | -0.44× | 1.85× | ||
| Q3 25 | 26.69× | 2.97× | ||
| Q2 25 | 9.65× | 2.49× | ||
| Q1 25 | 2.48× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.11× | 1.57× | ||
| Q2 24 | 1.21× | 2.87× | ||
| Q1 24 | 0.40× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
